241 related articles for article (PubMed ID: 35224540)
1. A Review Into the Effects of Pamidronic Acid and Zoledronic Acid on the Oral Mucosa in Medication-Related Osteonecrosis of the Jaw.
Bullock G; Miller CA; McKechnie A; Hearnden V
Front Oral Health; 2021; 2():822411. PubMed ID: 35224540
[TBL] [Abstract][Full Text] [Related]
2. Synthetic Hydroxyapatite Inhibits Bisphosphonate Toxicity to the Oral Mucosa In Vitro.
Bullock G; Miller C; McKechnie A; Hearnden V
Materials (Basel); 2020 May; 13(9):. PubMed ID: 32369961
[TBL] [Abstract][Full Text] [Related]
3. Low-level laser therapy prevents medication-related osteonecrosis of the jaw-like lesions via IL-1RA-mediated primary gingival wound healing.
Zheng Y; Dong X; Chen S; He Y; An J; Liu M; He L; Zhang Y
BMC Oral Health; 2023 Jan; 23(1):14. PubMed ID: 36627695
[TBL] [Abstract][Full Text] [Related]
4.
Rattanawonsakul K; Bullock G; Bolt R; Claeyssens F; Atkins S; Hearnden V
Front Oral Health; 2022; 3():892615. PubMed ID: 35795156
[TBL] [Abstract][Full Text] [Related]
5. Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.
Hokugo A; Kanayama K; Sun S; Morinaga K; Sun Y; Wu Q; Sasaki H; Okawa H; Evans C; Ebetino FH; Lundy MW; Sadrerafi K; McKenna CE; Nishimura I
Bone; 2019 Jun; 123():115-128. PubMed ID: 30926440
[TBL] [Abstract][Full Text] [Related]
6. Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy.
Tamari T; Elimelech R; Cohen G; Cohen T; Doppelt O; Eskander-Hashoul L; Zigdon-Giladi H
Sci Rep; 2019 Dec; 9(1):18896. PubMed ID: 31827217
[TBL] [Abstract][Full Text] [Related]
7. Imaging modalities for drug-related osteonecrosis of the jaw (2), Overview of the position paper on medication-related osteonecrosis of the jaw and the current status of the MRONJ in Japan.
Shibahara T
Jpn Dent Sci Rev; 2019 Nov; 55(1):71-75. PubMed ID: 30949254
[TBL] [Abstract][Full Text] [Related]
8. Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis.
Kuroshima S; Sasaki M; Murata H; Sawase T
Gerodontology; 2019 Dec; 36(4):313-324. PubMed ID: 31373407
[TBL] [Abstract][Full Text] [Related]
9. Alendronate or Zoledronic acid do not impair wound healing after tooth extraction in postmenopausal women with osteoporosis.
Lesclous P; Cloitre A; Catros S; Devoize L; Louvet B; Châtel C; Foissac F; Roux C
Bone; 2020 Aug; 137():115412. PubMed ID: 32404281
[TBL] [Abstract][Full Text] [Related]
10. Conservative surgical treatment of medication related osteonecrosis of the jaw (MRONJ) lesions in patients affected by osteoporosis exposed to oral bisphosphonates: 24 months follow-up.
Nisi M; Karapetsa D; Gennai S; Ramaglia L; Graziani F; Gabriele M
J Craniomaxillofac Surg; 2018 Jul; 46(7):1153-1158. PubMed ID: 29802059
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates induce senescence in normal human oral keratinocytes.
Kim RH; Lee RS; Williams D; Bae S; Woo J; Lieberman M; Oh JE; Dong Q; Shin KH; Kang MK; Park NH
J Dent Res; 2011 Jun; 90(6):810-6. PubMed ID: 21427353
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw.
Zhang W; Gao L; Ren W; Li S; Zheng J; Li S; Jiang C; Yang S; Zhi K
Front Immunol; 2021; 12():606043. PubMed ID: 33717086
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Effect of Benidipine on Medication-Related Osteonecrosis of the Jaw.
Matsunaka K; Imai M; Sanda K; Yasunami N; Furuhashi A; Atsuta I; Wada H; Ayukawa Y
Pharmaceuticals (Basel); 2022 Aug; 15(8):. PubMed ID: 36015167
[TBL] [Abstract][Full Text] [Related]
14. The influence of bisphosphonates on viability, migration, and apoptosis of human oral keratinocytes--in vitro study.
Pabst AM; Ziebart T; Koch FP; Taylor KY; Al-Nawas B; Walter C
Clin Oral Investig; 2012 Feb; 16(1):87-93. PubMed ID: 21225298
[TBL] [Abstract][Full Text] [Related]
15. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.
Kawahara M; Kuroshima S; Sawase T
Int J Implant Dent; 2021 May; 7(1):47. PubMed ID: 33987769
[TBL] [Abstract][Full Text] [Related]
16. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
[TBL] [Abstract][Full Text] [Related]
17. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence-guided surgery for the treatment of medication-related osteonecrosis of the jaw: A prospective cohort study.
Otto S; Ristow O; Pache C; Troeltzsch M; Fliefel R; Ehrenfeld M; Pautke C
J Craniomaxillofac Surg; 2016 Aug; 44(8):1073-80. PubMed ID: 27263757
[TBL] [Abstract][Full Text] [Related]
19. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines.
Rosella D; Papi P; Giardino R; Cicalini E; Piccoli L; Pompa G
J Int Soc Prev Community Dent; 2016; 6(2):97-104. PubMed ID: 27114946
[TBL] [Abstract][Full Text] [Related]
20. The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.
Yüce MO; Adalı E; Işık G
Clin Oral Investig; 2021 Jul; 25(7):4529-4541. PubMed ID: 33392802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
